| scholarly article | Q13442814 |
| P50 | author | Kevin J. Tracey | Q6396583 |
| Ulf Andersson | Q37375023 | ||
| Heikki Rauvala | Q38644081 | ||
| P2093 | author name string | H Yang | |
| J Andersson | |||
| C J Treutiger | |||
| G E Mullins | |||
| H Erlandsson-Harris | |||
| A Rouhiainen | |||
| A-S M Johansson | |||
| J E W Palmblad | |||
| P2860 | cites work | Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways | Q22010208 |
| High-mobility group chromatin proteins 1 and 2 functionally interact with steroid hormone receptors to enhance their DNA binding in vitro and transcriptional activity in mammalian cells | Q24522581 | ||
| Release of chromatin protein HMGB1 by necrotic cells triggers inflammation | Q28131815 | ||
| HMG-1 as a late mediator of endotoxin lethality in mice | Q28139166 | ||
| Effects of ethanol on NF-kappaB activation, production of myeloid growth factors, and adhesive events in human endothelial cells | Q28346565 | ||
| The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system | Q28567291 | ||
| The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells | Q28570659 | ||
| High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes | Q28574795 | ||
| New EMBO members' review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal | Q34334123 | ||
| High mobility group 1 protein is not stably associated with the chromosomes of somatic cells. | Q36274047 | ||
| Multivalent DNA-binding properties of the HMG-1 proteins | Q37539021 | ||
| Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells | Q40686939 | ||
| The adhesive and neurite-promoting molecule p30: analysis of the amino-terminal sequence and production of antipeptide antibodies that detect p30 at the surface of neuroblastoma cells and of brain neurons | Q41580157 | ||
| HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice | Q44116679 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | endothelium | Q111140 |
| P304 | page(s) | 375-385 | |
| P577 | publication date | 2003-10-01 | |
| P1433 | published in | Journal of Internal Medicine | Q6295387 |
| P1476 | title | High mobility group 1 B-box mediates activation of human endothelium | |
| P478 | volume | 254 |
| Q92670822 | A cross-sectional study of vitreous and serum high mobility group box-1 levels in proliferative diabetic retinopathy |
| Q34207592 | A simple method for establishing adherent ex vivo explant cultures from human eye pathologies for use in subsequent calcium imaging and inflammatory studies |
| Q35346469 | Activated protein C inhibits high mobility group box 1 signaling in endothelial cells |
| Q37687776 | Ambient particulate air pollution and microRNAs in elderly men. |
| Q41082545 | Ameliorative Effect of Aspalathin and Nothofagin from Rooibos (Aspalathus linearis) on HMGB1-Induced Septic Responses In Vitro and In Vivo |
| Q35052743 | Anti-HMGB1 neutralizing antibody ameliorates gut barrier dysfunction and improves survival after hemorrhagic shock |
| Q43611586 | Anti-inflammatory effects of rutin on HMGB1-induced inflammatory responses in vitro and in vivo |
| Q35951563 | Anti-inflammatory role of fetuin-A in injury and infection |
| Q43503364 | Anti-septic effects of pellitorine in HMGB1-induced inflammatory responses in vitro and in vivo |
| Q47574722 | Antibodies against RAGE in sepsis and inflammation: implications for therapy |
| Q41071962 | Antiseptic effect of vicenin-2 and scolymoside from Cyclopia subternata (honeybush) in response to HMGB1 as a late sepsis mediator in vitro and in vivo |
| Q47108366 | Association of HMGB1 with oxidative stress markers and regulators in PDR. |
| Q38603996 | Astrocytes, therapeutic targets for neuroprotection and neurorestoration in ischemic stroke |
| Q35982936 | Astrocytic high-mobility group box 1 promotes endothelial progenitor cell-mediated neurovascular remodeling during stroke recovery |
| Q43584707 | Barrier protective effects of rosmarinic acid on HMGB1-induced inflammatory responses in vitro and in vivo |
| Q36954659 | Bench-to-bedside review: High-mobility group box 1 and critical illness |
| Q38206875 | Beyond tissue injury-damage-associated molecular patterns, toll-like receptors, and inflammasomes also drive regeneration and fibrosis |
| Q37800989 | Biphasic actions of HMGB1 signaling in inflammation and recovery after stroke |
| Q37349924 | Caging a Beast in the Inflammation Arena: Use of Chinese Medicinal Herbs to Inhibit a Late Mediator of Lethal Sepsis, HMGB1. |
| Q37104160 | Cardiac nuclear high mobility group box 1 prevents the development of cardiac hypertrophy and heart failure |
| Q38040046 | Cardiovascular disease and high-mobility group box 1--is a new inflammatory killer in town? |
| Q42546594 | Circulating level of high mobility group box‑1 predicts the severity of community‑acquired pneumonia: Regulation of inflammatory responses via the c‑Jun N‑terminal signaling pathway in macrophages. |
| Q91142640 | Cysteinyl leukotriene receptor 2 drives lung immunopathology through a platelet and high mobility box 1-dependent mechanism |
| Q26744644 | Disruption of a Regulatory Network Consisting of Neutrophils and Platelets Fosters Persisting Inflammation in Rheumatic Diseases |
| Q46901701 | Early release of HMGB-1 from neurons after the onset of brain ischemia |
| Q44694257 | Effects of lower concentration thrombin on high-mobility group box 1 protein-mediated inflammatory responses |
| Q36743870 | Elevated levels of high-mobility group box-1 (HMGB1) in patients with severe or uncomplicated Plasmodium falciparum malaria |
| Q37229916 | Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer |
| Q33284424 | Endogenous secretory receptor for advanced glycation endproducts as a novel prognostic marker in chondrosarcoma |
| Q40119859 | Endogenous signals released from necrotic cells augment inflammatory responses to bacterial endotoxin |
| Q37448224 | Ethanol extracts from Portulaca oleracea L. attenuated ischemia/reperfusion induced rat neural injury through inhibition of HMGB1 induced inflammation |
| Q41864669 | Ethyl pyruvate inhibits retinal pathogenic neovascularization by downregulating HMGB1 expression |
| Q42619210 | Expression of high-mobility groups box-1/receptor for advanced glycation end products/osteopontin/early growth response-1 pathway in proliferative vitreoretinal epiretinal membranes. |
| Q47103796 | Genetic predisposition to ischaemic stroke by RAGE and HMGB1 gene variants in Chinese Han population |
| Q34591167 | Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats |
| Q55322256 | HMGB1 Increases IL-1β Production in Vascular Smooth Muscle Cells via NLRP3 Inflammasome. |
| Q44277736 | HMGB1 and LPS induce distinct patterns of gene expression and activation in neutrophils from patients with sepsis-induced acute lung injury |
| Q33844590 | HMGB1 contributes to glomerular endothelial cell injury in ANCA-associated vasculitis through enhancing endothelium-neutrophil interactions |
| Q33846620 | HMGB1 cytoplasmic translocation in patients with acute liver failure |
| Q54198044 | HMGB1 gene polymorphism is associated with hypertension in Han Chinese population. |
| Q34622835 | HMGB1 in health and disease |
| Q36309461 | HMGB1 in renal ischemic injury |
| Q45347650 | HMGB1 increases permeability of the endothelial cell monolayer via RAGE and Src family tyrosine kinase pathways |
| Q36919024 | HMGB1 induces human lung endothelial cell cytoskeletal rearrangement and barrier disruption |
| Q35953553 | HMGB1 is a therapeutic target for sterile inflammation and infection |
| Q38939435 | HMGB1, IL-1α, IL-33 and S100 proteins: dual-function alarmins |
| Q48496752 | HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. |
| Q37418804 | HMGB1, an innate alarmin, in the pathogenesis of type 1 diabetes. |
| Q47859005 | HMGB1-stimulated human primary cardiac fibroblasts exert a paracrine action on human and murine cardiac stem cells |
| Q36827934 | HMGB1: a signal of necrosis |
| Q24645232 | HMGB1: endogenous danger signaling |
| Q33579223 | Hemorrhagic shock augments lung endothelial cell activation: role of temporal alterations of TLR4 and TLR2. |
| Q39629019 | Heparin changes the conformation of high-mobility group protein 1 and decreases its affinity toward receptor for advanced glycation endproducts in vitro |
| Q37215654 | High Mobility Group Box Protein 1 Boosts Endothelial Albumin Transcytosis through the RAGE/Src/Caveolin-1 Pathway |
| Q36481939 | High Mobility Group Box Protein-1 correlates with renal function in chronic kidney disease (CKD). |
| Q54583647 | High mobility group box 1 is a novel substrate of dipeptidyl peptidase-IV. |
| Q33836853 | High mobility group box 1 protein as a potential drug target for infection- and injury-elicited inflammation |
| Q41952666 | High mobility group box 1 protein induction by Mycobacterium bovis BCG. |
| Q28280114 | High mobility group box 1 protein interacts with multiple Toll-like receptors |
| Q39831106 | High mobility group box protein 1 in complex with lipopolysaccharide or IL-1 promotes an increased inflammatory phenotype in synovial fibroblasts. |
| Q92619014 | High mobility group protein B1 (HMGB1) interacts with receptor for advanced glycation end products (RAGE) to promote airway smooth muscle cell proliferation through ERK and NF-κB pathways |
| Q55010929 | High-Mobility Group Box 1 in Dry Eye Inflammation. |
| Q53665301 | High-Mobility Group Box-1 Modulates the Expression of Inflammatory and Angiogenic Signaling Pathways in Diabetic Retina. |
| Q58760274 | High-Mobility Group Box-1 and Liver Disease |
| Q36703858 | High-mobility group box 1 from reactive astrocytes enhances the accumulation of endothelial progenitor cells in damaged white matter |
| Q36174486 | High-mobility group box 1 inhibits HCO(3)(-) absorption in medullary thick ascending limb through a basolateral receptor for advanced glycation end products pathway |
| Q28242907 | High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal |
| Q37802381 | High-mobility group box 1, oxidative stress, and disease |
| Q27008225 | High-mobility group box 1: an amplifier of stem and progenitor cell activity after stroke |
| Q37206315 | High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease |
| Q35108807 | High-mobility group box-1 and biomarkers of inflammation in the vitreous from patients with proliferative diabetic retinopathy |
| Q36340353 | High-mobility group box-1 and endothelial cell angiogenic markers in the vitreous from patients with proliferative diabetic retinopathy |
| Q36900033 | High-mobility group box-1 induces decreased brain-derived neurotrophic factor-mediated neuroprotection in the diabetic retina. |
| Q34500661 | High-mobility group box-1 protein (HMGB1) is increased in antineutrophilic cytoplasmatic antibody (ANCA)-associated vasculitis with renal manifestations |
| Q43943397 | High-mobility group box-1 protein in tracheal aspirates from premature infants: relationship with bronchopulmonary dysplasia and steroid therapy |
| Q34003036 | High-mobility group box-1 protein serum levels do not reflect monocytic function in patients with sepsis-induced immunosuppression |
| Q37768056 | High-mobility-group box chromosomal protein 1 as a new target for modulating stress response |
| Q43458878 | Hyperlipidemia stimulates the extracellular release of the nuclear high mobility group box 1 protein |
| Q42256407 | Inhibition of reactive astrocytes with fluorocitrate retards neurovascular remodeling and recovery after focal cerebral ischemia in mice. |
| Q43049804 | Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection |
| Q53410760 | Inhibitory effects of polyozellin from Polyozellus multiplex on HMGB1-mediated septic responses. |
| Q36394688 | Instigation of endothelial Nlrp3 inflammasome by adipokine visfatin promotes inter-endothelial junction disruption: role of HMGB1. |
| Q37003895 | Intratracheal instillation of ethyl pyruvate nanoparticles prevents the development of shunt-flow-induced pulmonary arterial hypertension in a rat model |
| Q34704572 | Intravenous ascorbic acid to prevent and treat cancer-associated sepsis? |
| Q38922865 | Knockdown of HMGB1 improves apoptosis and suppresses proliferation and invasion of glioma cells |
| Q36431384 | LPS-Primed Release of HMGB-1 from Cortical Astrocytes is Modulated Through PI3K/AKT Pathway |
| Q41889316 | Lipopolysaccharide activates Toll-like receptor 4 (TLR4)-mediated NF-κB signaling pathway and proinflammatory response in human pericytes |
| Q28281853 | Mechanisms of Disease: the role of high-mobility group protein 1 in the pathogenesis of inflammatory arthritis |
| Q35981607 | MiR-129-2 functions as a tumor suppressor in glioma cells by targeting HMGB1 and is down-regulated by DNA methylation |
| Q64100562 | MicroRNA-10b-5p downregulation inhibits the invasion of glioma cells via modulating homeobox B3 expression |
| Q37675611 | NETosis in Alzheimer's Disease. |
| Q33814903 | Novel HMGB1-inhibiting therapeutic agents for experimental sepsis |
| Q27009468 | Novel Mechanisms of Herbal Therapies for Inhibiting HMGB1 Secretion or Action |
| Q39828453 | Nucleophosmin may act as an alarmin: implications for severe sepsis |
| Q58735789 | Optimizing transfusion strategies in damage control resuscitation: current insights |
| Q42469702 | Osteopontin and other regulators of angiogenesis and fibrogenesis in the vitreous from patients with proliferative vitreoretinal disorders |
| Q35940134 | PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease |
| Q35922382 | Pathophysiology of Endometriosis: Role of High Mobility Group Box-1 and Toll-Like Receptor 4 Developing Inflammation in Endometrium. |
| Q34559545 | Pathophysiology of mifepristone-induced septic shock due to Clostridium sordellii |
| Q47118391 | Pivotal neuroinflammatory and therapeutic role of high mobility group box 1 in ischemic stroke |
| Q35610215 | Potential role of high mobility group box 1 in viral infectious diseases |
| Q42840421 | Prognostic value of the high-mobility group box-1 in young patients with chest pain |
| Q35235003 | Prolonged neuroinflammation after lipopolysaccharide exposure in aged rats. |
| Q44021066 | Protective effect of Tanshinone IIA against infarct size and increased HMGB1, NFκB, GFAP and apoptosis consequent to transient middle cerebral artery occlusion |
| Q58698867 | Protein Profile of Blood Monocytes is Altered in HTLV-1 Infected Patients: Implications for HAM/TSP Disease |
| Q26744630 | RAGE Expression and ROS Generation in Neurons: Differentiation versus Damage |
| Q28568915 | RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages |
| Q46489790 | ROS-dependent HMGB1 secretion upregulates IL-8 in upper airway epithelial cells under hypoxic condition |
| Q35044718 | Red blood cells induce necroptosis of lung endothelial cells and increase susceptibility to lung inflammation. |
| Q36228547 | Regulation of osteoclast function and bone mass by RAGE. |
| Q36085036 | Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis |
| Q34257997 | Repeated intratracheal instillation of PM10 induces lipid reshaping in lung parenchyma and in extra-pulmonary tissues |
| Q39221209 | Response of the cerebral vasculature following traumatic brain injury |
| Q42925964 | Role of ERK map kinase and CRM1 in IL-1beta-stimulated release of HMGB1 from cortical astrocytes |
| Q35610210 | Role of HMGB1 in cardiovascular diseases |
| Q52642996 | Role of Inflammation in Diabetic Retinopathy. |
| Q38051217 | Role of high mobility group box 1 in inflammatory disease: focus on sepsis |
| Q38611307 | Role of high-mobility group box-1 protein in disruption of vascular barriers and regulation of leukocyte-endothelial interactions. |
| Q41012127 | Role of inflammation in the pathogenesis of diabetic retinopathy |
| Q37622744 | Targeting HMGB1 in the treatment of sepsis |
| Q37516590 | The Expression of HMGB1 in Bone Marrow MSCs Is Upregulated by Hypoxia with Regulatory Effects on the Apoptosis and Adhesion. |
| Q33745462 | The HMGB1-RAGE axis mediates traumatic brain injury-induced pulmonary dysfunction in lung transplantation |
| Q57283116 | The Janus face of HMGB1 in heart disease: a necessary update |
| Q37560287 | The Role of HMGB1 in the Pathogenesis of Type 2 Diabetes. |
| Q38352705 | The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. |
| Q53464698 | The expression of high-mobility group box protein-1 in temporomandibular joint osteoarthritis with disc perforation. |
| Q40453622 | The inflammatory reflex--introduction. |
| Q37661644 | The proinflammatory cytokine high-mobility group box-1 mediates retinal neuropathy induced by diabetes |
| Q93004249 | The role of TLR4 and HO-1 in neuroinflammation after subarachnoid hemorrhage |
| Q37140804 | The role of cell death in the pathogenesis of autoimmune disease: HMGB1 and microparticles as intercellular mediators of inflammation |
| Q36981872 | Therapeutic potential of HMGB1-targeting agents in sepsis |
| Q37347450 | Thrombin inhibits HMGB1-mediated proinflammatory signaling responses when endothelial protein C receptor is occupied by its natural ligand |
| Q36145679 | Toll-like receptor 4 signaling: A common pathway for interactions between prooxidants and extracellular disulfide high mobility group box 1 (HMGB1) protein-coupled activation |
| Q43514043 | Transforming growth factor β-induced protein promotes severe vascular inflammatory responses |
| Q36744024 | Treatment of severe sepsis: where next? Current and future treatment approaches after the introduction of drotrecogin alfa |
| Q45158260 | Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1. |
| Q36245387 | Understanding RAGE, the receptor for advanced glycation end products |
| Q84951932 | Vascular anti-inflammatory effects of curcumin on HMGB1-mediated responses in vitro |
| Q54381687 | Vascular barrier protective effects of piperlonguminine in vitro and in vivo. |
| Q90793170 | β-Catenin phosphorylation at Y654 and Y142 is crucial for high mobility group box-1 protein-induced pulmonary vascular hyperpermeability |
Search more.